Gattex® (teduglutide) is a drug for the treatment of short bowel syndrome (SBS). Short bowel syndrome is a rare condition related to poor absorption of nutrients. It typically occurs in people who have had half or more of their small intestine removed, and cannot absorb enough water, vitamins, and other nutrients from food. They may then need to use parenteral nutrition (PN) and intravenous (IV) fluids, the slow infusion of a solution of nutrients and fluids into a vein.

Gattex works by regeneration of cells in the intestinal lining, slowing down transit through the gut and increasing blood flow, allowing for increased nutrient absorption. In studies, the drug was associated with achieving and maintaining clinically meaningful reductions in PN and IV fluid volume in adult subjects with short bowel syndrome.

Participants Sought for a Short Bowel Syndrome (SBS) Research Study for Children Up To 17 Years of Age on Parenteral Nutrition

Description: Short bowel syndrome is a rare disorder. This 24-week, double-blind study is evaluating the safety and effectiveness of teduglutide in children up to the ages of 17 with short bowel syndrome (SBS). Teduglutide is currently an approved medicine for adults with SBS. The aim of the study is to increase absorption of nutrients which may result in decreased parenteral support.

Study Population: The study is in a pediatric patient population of males and females with SBS dependent on Parenteral Support – the upper age limit is 17 years of age. The study will take place in the US, Canada, Finland, Italy, UK, France, and Germany.

Phase: Phase III

Sponsor: Shire

Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.. Please refer to this study by its ClinicalTrials.gov identifier: NCT02682381

Participants Sought for a Long-term Study of Patients with Short Bowel Syndrome (SBS)

March 3, 2014 – This global clinical study has begun enrolling patients with SBS in order to provide additional long-term data on safety of teduglutide and on the natural history of SBS in patients in routine, real world settings. The information gathered is intended to assist health care providers in optimizing their clinical decision-making in managing SBS patients.

Description:  A prospective, multi-center registry for patients with short bowel syndrome. The primary objective of the observational study is to evaluate the long-term safety profile for patients with SBS treated with teduglutide in a routine clinical setting, as well as to characterize long-term clinical outcomes in patients with SBS. Enrollment will include SBS patients treated and not treated with teduglutide. Study Population: Male and female patients of any age with a diagnosis of SBS, including those who have never taken teduglutide, as well those who have or are using teduglutide. Study Follow-up Duration: 10 years Sponsored by: Shire Contact: Shire Email: This email address is being protected from spambots. You need JavaScript enabled to view it. and refer to this ClinicalTrials.gov Identifier: NCT01990040. Additional Information on NIH Clinical Trial Registry.

Teduglutide Granted Orphan Drug Status in Japan

January 5, 2015 – The Japanese Ministry of Health, Labor, and Welfare (MHLW) granted teduglutide (Gattex in the US; Revestive in the EU) orphan drug status for the treatment of adult patients with short bowel syndrome (SBS).

FDA Approves Updated Labeling for Gattex to Include Long-Term Data

June 30, 2014 – The U.S. Food and Drug Administration (FDA) has approved updated labeling for Gattex (teduglutide [rDNA origin]) for injection, to include long-term data from adult patients with Short Bowel Syndrome (SBS). The data, published in 2013, demonstrated that there was an increased response to treatment over time in all groups receiving Gattex. The revised labeling provides this important information for healthcare professionals and patients about long-term use of Gattex.

Supplemental New Drug Application Accepted for Gattex (teduglutide)

November 13, 2013 — The FDA has accepted for consideration a supplemental New Drug Application (sNDA) for Gattex. The application seeks to include new, long term usage data on the product label. This new data, from a 2 year study presented at the ACG meeting in October, showed that patients using Gattex beyond one year continued to be able to reduce their support on parenteral nutrition.

New Findings Support Long-Term Use and Effectiveness of Gattex

October 24, 2013 — New findings from a two-year study by NPS Pharmaceuticals support the long-term use of Gattex (teduglutide [rDNA origin]) for injection in adult patients with Short Bowel Syndrome (SBS). The data were presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting and Postgraduate Course in San Diego, CA in October 2013.

The open-label extension study included 88 adult patients with SBS. Investigators reported that the long-term use of Gattex in patients with SBS resulted in additional, clinically meaningful reductions in the volume and days per week of parenteral support requirements in this extension study. Thirteen (13) patients in the study achieved complete independence from parenteral support with long-term Gattex therapy. No new unexpected safety concerns were observed with long-term Gattex treatment and the product’s safety profile remains consistent with the product’s label.

This study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal. The poster, entitled “Long-term Safety and Efficacy of Teduglutide for the Treatment of Intestinal Failure Associated with Short Bowel Syndrome: Final Results of the Steps-2 Study, a 2-year, Multicenter, Open-label Clinical Trial,” was recognized as an ACG Presidential Poster Award recipient, which identifies the most highly-ranked abstracts in poster sessions.

Study Reports Safety and Efficacy of Teduglutide over 52 Week Treatment Period

January 24, 2013 – An international multi-center study involving 52 patients looked at the safety, tolerability, and efficacy of teduglutide (Gattex) taken once per day over 52 weeks for the treatment of people with short bowel syndrome receiving parenteral nutrition (PN). The study concluded that for patients with short bowel syndrome and intestinal failure, the efficacy of teduglutide was maintained over 52 weeks and the safety profile was sufficient for it to be considered for long-term use. 

A reduction of more than 20%, equivalent to 1 day per week, of parenteral nutrition dependency was achieved in a significant number of participants receiving the drug. Four (4) patients were able to discontinue PN fluids completely over the 52 weeks.

The most common adverse events reported included headache, nausea, and abdominal pain. Of 7 patients who withdrew because of adverse events, 4 were considered treatment related. While the researchers found the safety profile to be acceptable, they advise that physicians closely monitor patients beginning the drug for side effects and possible need to adjust dose.

Patients taking part in clinical trials are closely monitored. Continued clinical practice studies are needed to understand real world implications for improving quality of life and reducing potential long-term PN complications for people with short bowel syndrome.

The study titled, “Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel syndrome intestinal failure,” was reported in the journal, Clinical Gastroenterology and Hepatology, Jan 17, 2013.

FDA Approves Gattex to Treat Short Bowel Syndrome

December 21, 2012 – The U.S. Food and Drug Administration (FDA) today approved Gattex (teduglutide) for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. Gattex will be available in the first quarter of 2013. To help ensure that the benefits of Gattex outweigh the risks for causing other serious conditions, the drug is approved with a Risk Evaluation and Mitigation Strategy, which patients need to discuss with their doctors.

The New Drug Application for Gattex to Treat Short Bowel Syndrome is under Review by the U.S. Food and Drug Administration (FDA)

On October 16, 2012, the FDA’s Gastrointestinal Drugs Advisory Committee voted unanimously to recommend approval of Gattex for adults with SBS. The drug is currently under review by the FDA, which is expected to make a final decision on the drug by this year end. 

Gattex is a novel, recombinant analog of human glucagon-like peptide 2, a peptide involved in gastrointestinal regeneration and repair. NPS Pharmaceuticals is a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders.

The company's SBS clinical development program represents the largest and most comprehensive to date. The information in the NDA is derived from 14 completed and one ongoing clinical study. A total of 566 subjects have been treated with teduglutide. Of the 566 Gattex-treated subjects, 97 SBS subjects had at least 12 months of exposure to Gattex. Across the company’s Phase 3 studies, a total of 15 patients were able to achieve independence from PH/IV. Gattex may potentially cause other serious condtions. The most common side effects include abdominal pain, upper respiratory tract infections, nausea, injection site reactions, headaches, gastrointestinal stoma complications, and abdominal distension.

About SBS

SBS is a rare disorder characterized by inadequate absorption of fluids and nutrients in people who have had a significant portion of their small intestine surgically removed due to disease or injury. It is a highly disabling condition that can lead to serious life-threatening complications and impair a patient's quality-of-life. SBS typically arises after extensive resection of the bowel due to Crohn's disease, ischemia, or other conditions. The condition is associated with intestinal failure and the inability to absorb sufficient nutrients and/or fluids through the gastrointestinal tract.

People with SBS are highly prone to malnutrition, diarrhea, dehydration, and an inability to maintain weight due to the reduced intestinal capacity to absorb macronutrients, water, and electrolytes. As a result, many patients require the long-term use of parenteral nutrition (PN) and intravenous (IV) fluids to supplement their nutritional needs and stabilize their hydration. Although PN/IV can meet basic nutrition and fluid requirements, it does not improve the body's ability to absorb nutrients.

The long-term use of PN/IV fluids is associated with serious and life-threatening complications. Patients on parenteral support often experience a poor quality of life with difficulty sleeping, frequent urination, and loss of independence.

Learn more about short bowel syndrome here.

What are Phases?

Treatment trials or studies are in phases:

  • Phase 1 tests a new drug or treatment in a small group to evaluate its safety, determine a safe dosage range, and identify side effects;
  • Phase 2 expands the study to a larger group of people to see if it is effective and to further evaluate its safety;
  • Phase 3 expands the study to an even larger group of people to confirm its effectiveness, monitor side effects, and collect information that will allow the drug or treatment to be used safely.
News
Industry Treatment News
Eluxadoline (Viberzi)
Eosinophilic Esophagitis Study
Gattex
Linaclotide (Linzess)
Linaclotide Study for IBS in Children
Linaclotide Study for FC in Children
Medical News
Medical News - Archive
Events
Special Events & Meetings
Press Releases
2016-0801 Learn the Facts About Gastroparesis
2016-0405 Think You Have IBS? Find Out For Sure Before Starting a Treatment
2015-1123 Is it More than Simple Heartburn? Ask Your Doctor.
2015-7-30 Gastroparesis is a Hidden Medical Condition for Many
2015-0330 Online Survey Looks to Help Improve Outcomes for those with IBS
2014-1119 Persistent Heartburn May Be a Sign of GERD
2014-0826 Lack of Awareness of Gastroparesis May Impact Medical Care
2014-0326 IFFGD Marks IBS Awareness Month with Launch of Mobile App
2014-0225 IFFGD Research Grants to Study Gastroparesis
2013-1106 15 Tips for GERD Awareness Week
2013-0626 New DHA.org
2013-0412 IFFGD Presents 2013 Research Awards
2013-0401 Turning Attention to Returning Vets
2012-1109 Banish Frequent Heartburn by Burning More Calories
2012-0321 April is IBS Awareness Month: A Serious Issue for Veterans
2006-0418 Natl Commission
2001-1119 Heartburn or Heart Attack
2006-0321 Women's Health
2011-1130 Is Your Child's Reflux/Spitting Up A Point of Concern?
2006-0202 IBS or Something Else
2011-0412 IFFGD Research Award Winners
2005-1125 GERD Costs
2005-0412 IBS Awareness
2011-0329 IBS Signs You Should Not Ignore
2010-1118 GERD Difference
2004-1125 Heartburn & Heartache
2004-0929 Norton Honored
2009-1109 GERD at Night
2010-0517 US House Resolution for IBS
2010-1001 Heartburn or GERD?
2006-1116 GERD & Holidays
2007-0401 IBS Myths
2009-0417 IFFGD Research Award Recipients
2004-0525 IBS Travel Tips
2007-1118 When Is Simple Heartburn Not So Simple?
2008-0331 Dealing with Digestive Disorders
2004-0101 IFFGD Conference
2004-0408 IBS Medical Care
2007-0718 Proposed FDA Funding Applauded
2003-1117 GERD Treatment
2003-0401 IFFGD Research Awards
2003-0401 IBS Awareness
2002-1102 Heartburn Caution
2002-0423 IBS in Real World
2002-0423 IBS-C Treatment
2002-0402 IBS & Lost Potential
2001-0322 Patients First
1998-0401 IBS Millions Suffer
1997-1114 Research & Women's Health
Commentary
Misunderstood Functional GI Disorders
IBS is No Joking Matter
For Media
Reporters' Guides
Media Contact Form

Join the conversation

join conversation

Keep up-to-date on the latest news, stories, tips, research highlights, and more!

Sign up for eNewsletter

Connect through Facebook

Follow us on twitter